Y-Intercept (HK)’s ImmunityBio IBRX Stock Holding History

Y-Intercept (HK)’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Buy	+188,966	New	+$1.43M	0.03%	812
2023 Q2	–	Sell	-39,242	Closed	-$71.4K	–	1471
2023 Q1	$71.4K	Buy	+39,242	New	+$122K	0.01%	1084
2022 Q3	–	Sell	-19,223	Closed	-$72K	–	1108
2022 Q2	$72K	Buy	+19,223	New	+$77.2K	0.01%	734

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Y-Intercept (HK)'s IBRX Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in ImmunityBio (IBRX) in Q2 2026: 188,966 shares worth $1.65M. The stake represents 0.03% of the portfolio and ranks #812 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in IBRX as recently as Q1 2023.

Y-Intercept (HK) first reported a position in IBRX in Q2 2022 and has held it in 3 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Y-Intercept (HK) held 188,966 shares of ImmunityBio worth $1.65M as of Q2 2026.
ImmunityBio was a new Y-Intercept (HK) position in Q2 2026.
ImmunityBio made up 0.03% of Y-Intercept (HK)'s portfolio in Q2 2026, its #812 holding.
Y-Intercept (HK) first reported a position in ImmunityBio in Q2 2022 and has held it in 3 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.